Xolair’s revenue trends
Roche’s (RHHBY) Xolair generated revenues of 442 million Swiss francs in the first quarter compared to 437 million Swiss francs in the first quarter of 2017, which reflected ~1% YoY (year-over-year) growth and ~3% growth sequentially.
In the US market, Roche commercializes Xolair while Novartis commercializes it outside the US market. In the first quarter, Novartis (NVS) reported revenues of $255 million from the sales of Xolair, which reflected ~14% YoY growth.
Xolair (omalizumab) is used for the treatment of moderate to severe asthma in individuals aged above six years. In the asthma drug market, Xolair’s peers include Teva Pharmaceuticals’ (TEVA) Cinquir, and GlaxoSmithKline’s (GSK) Nucala.
Pulmozyme revenue trends
In the first quarter, Pulmozyme reported revenues of 169 million Swiss francs compared to 175 million Swiss francs in the first quarter of 2017, which reflected an ~3% YoY decline and 15% decline sequentially.
In the first quarter, in the US and European markets, Pulmozyme reported revenues of 106 million Swiss francs and 33 million Swiss francs, respectively, which is a decline of ~10% and 4% decline on a YoY basis.
Pulmozyme is used to treat cystic fibrosis. Some important drug for cystic fibrosis includes Vertex Pharmaceuticals’ (VRTX) Orkambi and Kalydeco.
CellCept revenue trends
In the first quarter, CellCept reported revenues of 158 million Swiss francs compared to 170 million Swiss francs in the first quarter of 2017, which reflected an ~7% YoY decline and a 13% decline sequentially.
In the first quarter, in the US, Europe, and Japan, CellCept generated revenues of 25 million Swiss francs, 44 million Swiss francs, and 17 million Swiss francs, respectively.
CellCept (mycophenolate mofetil) is used for the prevention of organ rejection in individuals receiving allogeneic renal, cardiac, or hepatic transplant. CellCept is used along with corticosteroids and cyclosporine.